Diabetes
Brexit/ Diabetes/ News/ News/ R&D
Novo Nordisk CEO reassures UK patients over Brexit insulin supplies
Richard Staines
Brexit, Diabetes, Novo Nordisk, R&D
0 Comment
AstraZeneca/ Diabetes/ Diabetes/ News/ News/ R&D/ UK & Europe
AstraZeneca improves diabetes pen to maintain its market share
Diabetes/ Diabetes/ News/ News/ Patients
FDA warns of genital gangrene risk with diabetes drug class
Piotr Wnuk
Diabetes, FDA warning, SGLT2 inhibitors
0 Comment
Diabetes/ News/ News/ R&D/ Top stories
Type 2 diabetes research: fewer side effects from modified medication
Joy Persaud
Diabetes, drug side effects, Type 2 diabetes
0 Comment
Diabetes/ News/ News/ News/ Novo Nordisk/ Patients/ R&D/ Top pharmaceutical companies/ Top stories
Real-world diabetes study CONFIRMs positive comparative efficacy for Novo’s Tresiba
Piotr Wnuk
Diabetes, Novo Nordisk, Sanofi, Toujeo, Tresiba
0 Comment
Diabetes/ Diabetes/ News/ News/ News/ Novo Nordisk/ Patients/ R&D/ Top pharmaceutical companies/ Top stories
Novo’s diabetes pill beats injections in head-to-head trials
Piotr Wnuk
Diabetes, diabetes care, GLP-1, Insuline, Januvia, Novo Nordisk, semaglutide, Sitagliptin, Type 2 diabetes, Victoza
0 Comment
Diabetes/ Diabetes/ Healthcare/ News/ News/ Patients
J&J seals $2.1bn deal on sale of major diabetes devices firm
Joy Persaud
blood glucose monitor, Diabetes, Glucose, J&J, Johnson and Johnson, Platinum Equity
0 Comment
Diabetes/ Market Access/ News/ News
Novo Nordisk undeterred after losing out on Ablynx takeover
Andrew McConaghie
Ablynx, Diabetes, Novo Nordisk, Ozempic
0 Comment
After losing out to Sanofi in its pursuit of Belgian biotech Ablynx earlier this week, Novo Nordisk has put a brave face on the disappointment.